Adaptimmune to engage in restructuring; 33% headcount reduction

skynesher Adaptimmune Therapeutics ( NASDAQ: ADAP ) said it will engage in a company restructuring that will result in a headcount reduction of 33% in Q1 2025. The company said that and other cost-saving measures will result in $300M total cost savings over the next.